The Non-Alcoholic Steatohepatitis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Non-Alcoholic Steatohepatitis Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Non-Alcoholic Steatohepatitis Market.

Some of the key takeaways from the Non-Alcoholic Steatohepatitis Pipeline Report:

• Companies across the globe are diligently working toward developing novel Non-Alcoholic Steatohepatitis treatment therapies with a considerable amount of success over the years. 
• Non-Alcoholic Steatohepatitis companies working in the treatment market are  Gmax Biopharm, Novartis Pharmaceuticals, Lin Biosciences, Viking Therapeutics, Seal Rock Therapeutics, AstraZeneca, Boehringer Ingelheim, Oramed Pharmaceuticals, ENYO Pharma, Terns Pharmaceuticals, NovoNordisk, Madrigal Pharmaceuticals, Inventiva Pharma, Gilead Sciences, Enanta Pharmaceuticals, Inc., Genfit, JD Bioscience Inc., Oramed, Ltd., Merck Sharp & Dohme LLC, Regeneron Pharmaceuticals, Enyo Pharma, Terns, Inc., Galectin Therapeutics Inc., Oasis Pharmaceuticals, LLC, and others, are developing therapies for the Non-Alcoholic Steatohepatitis treatment 

• Emerging Non-Alcoholic Steatohepatitis therapies such as – GMA-107, Tropifexor (LJN452), LBS-009, VK-1430, SRT-015, AZD 2693, BI 456906, ORMD-0801, EYP001, TERN-501, Semaglutide, Resmetirom, Lanifibranor, Semaglutide (SEMA), EDP-305, GFT505, GM-60106, ORMD-0801, MK-3655, ALN-HSD, EYP001a, TERN-201, GR-MD-02, OA-235i, and others are expected to have a significant impact on the Non-Alcoholic Steatohepatitis market in the coming years.   
• In January 2023, Madrigal Pharmaceuticals, Inc. announced additional results from the pivotal Phase III MAESTRO-NASH biopsyclinical trial of Resmetirom, a liver-directed selective thyroid hormone receptor agonist. The new MAESTRO-NASH data are being presented at the NASH-TAG Conference
• In July 2022, TERN Therapeutics initiated a Phase IIa multicenter, randomized, double-blind, placebo controlled clinical study to evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of orally administeredTERN-501 as monotherapy as well as in combination with TERN-101 in Noncirrhotic Adults with Presumed Non-Alcoholic Steatohepatitis (NASH)
• In August 2022 Madrigal Pharmaceuticals initiated a multi-national, multicenter, double-blind, randomized, placebo-controlled study in participants with well-compensated NASH cirrhosis
• In November 2022, Terns Pharmaceuticals, Inc. announced that the company is presenting positive clinical data from its Phase 1 study of TERN-501, a thyroid hormone receptor beta (THR-β) agonist in development for the treatment of NASH
• In January 2021, US Food and Drug Administration cleared the company’s Investigational New Drug application (IND) forTERN-501, a selective thyroid hormone receptor beta, or THR-β, agonist with enhanced metabolic stability and liver distribution, characteristics that are intended to improve safety and efficacy in NASH patients
•  has granted the request for Fast Track designation for Madrigal Pharmaceuticals’ resmetirom for the treatment of NASH

Non-Alcoholic Steatohepatitis Overview

Nonalcoholic steatohepatitis (NASH) is liver inflammation and damage caused by a fat buildup in the liver. It is part of a group of conditions called nonalcoholic fatty liver disease. Nonalcoholic fatty liver disease can be divided into the isolated fatty liver in which there is only accumulation of fat, and nonalcoholic steatohepatitis (NASH), in which there is fat, inflammation, and damage to liver cells.

Get a Free Sample PDF Report to know more about Non-Alcoholic Steatohepatitis Pipeline Therapeutic Assessment-

https://www.delveinsight.com/sample-request/non-alcoholic-steatohepatitis-nash-pipeline-insight

Emerging Non-Alcoholic Steatohepatitis Drugs Under Different Phases of Clinical Development Include:

• GMA-107: Gmax Biopharm
• LBS-009: Lin Biosciences
• VK-1430: Viking Therapeutics
• SRT-015: Seal Rock Therapeutics
• AZD 2693: AstraZeneca
• BI 456906: Boehringer Ingelheim
• ORMD-0801: Oramed Pharmaceuticals
• EYP001: ENYO Pharma
• TERN-501: Terns Pharmaceuticals
• Semaglutide: NovoNordisk
• Resmetirom: Madrigal Pharmaceuticals
• Lanifibranor: Inventiva Pharma

Route of Administration

Non-Alcoholic Steatohepatitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Molecule Type

Products have been categorized under various Molecule types, such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy 

Non-Alcoholic Steatohepatitis Pipeline Therapeutics Assessment

• Non-Alcoholic Steatohepatitis Assessment by Product Type
• Non-Alcoholic Steatohepatitis By Stage and Product Type
• Non-Alcoholic Steatohepatitis Assessment by Route of Administration
• Non-Alcoholic Steatohepatitis By Stage and Route of Administration
• Non-Alcoholic Steatohepatitis Assessment by Molecule Type
• Non-Alcoholic Steatohepatitis by Stage and Molecule Type

DelveInsight’s Non-Alcoholic Steatohepatitis Report covers around products under different phases of clinical development like-

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Non-Alcoholic Steatohepatitis product details are provided in the report. Download the Non-Alcoholic Steatohepatitis pipeline report to learn more about the emerging Non-Alcoholic Steatohepatitis therapies

Some of the key companies in the Non-Alcoholic Steatohepatitis Therapeutics Market include:

Key companies developing therapies for Non-Alcoholic Steatohepatitis are – 89bio Inc, ABIONYX Pharma SA, Abivax SA, Abliva AB, Acquist Therapeutics, AdAlta Ltd, Afimmune Biopharma Ltd, Akero Therapeutics Inc, Albireo Pharma Inc, Aldeyra Therapeutics Inc, Ascletis Pharma Inc, Zhejiang Doer Biologics Corp, Asdera LLC, Assembly Biosciences Inc, AstraZeneca Plc, Auransa Inc, Avaliv Therapeutics Inc, Avolynt Inc, ChemoCentryx Inc, ChemomAb Ltd, Dicerna Pharmaceuticals Inc, Dr. Falk Pharma GmbH, DURECT Corp, Eli Lilly and Co, Enanta Pharmaceuticals Inc EncuraGen Inc, Engitix Ltd, Hepion Pharmaceuticals Inc, Heprotech Inc, Hinova Pharmaceuticals Inc, HK inno.N Corp, HotSpot Therapeutics Inc, Ildong Pharmaceutical Co Ltd, Imago Pharmaceuticals Inc, ImmuneMed Inc, Immupharma Plc, Immuron Ltd, Indalo Therapeutics Inc, Inmune Bio Inc, Innovimmune Biotherapeutics Inc, Inorbit Therapeutics AB, Integral Molecular Inc, Intercept Pharmaceuticals Inc, INVENT Pharmaceuticals Inc, InventisBio Inc, Inventiva, LG Chem Ltd, LifeMax Laboratories Inc, Metabolys SAS, Metacrine Inc, Pattern Therapeutics, PegBio Co Ltd, Pfizer Inc, RadBio, Redx Pharma Plc, Regenasome Pty Ltd, Regulus Therapeutics Inc, SparkBioPharma Inc, SteroTherapeutics LLC, T3D Therapeutics Inc, TaiwanJ Pharmaceuticals Co Ltd, Thoth Science Inc, Wave Life Sciences Ltd, Xenexus Pharmaceuticals Pty Ltd, Xfibra Inc, XORTX Therapeutics Inc, YD Life Science Co, Yuhan Corp Zebra Discovery Ltd, and many others.

Non-Alcoholic Steatohepatitis Pipeline Analysis:

The Non-Alcoholic Steatohepatitis pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Non-Alcoholic Steatohepatitis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Non-Alcoholic Steatohepatitis Treatment.
• Non-Alcoholic Steatohepatitis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Non-Alcoholic Steatohepatitis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Non-Alcoholic Steatohepatitis market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Non-Alcoholic Steatohepatitis drugs and therapies

Non-Alcoholic Steatohepatitis Pipeline Market Drivers

• Rise in Non-Alcoholic Steatohepatitis prevalence, emerging treatment therapies of NASH, growing demand for NASH therapeutics are some of the important factors that are fueling the Non-Alcoholic Steatohepatitis Market.

Non-Alcoholic Steatohepatitis Pipeline Market Barriers

• However, Lack of analogs, use of combination therapies, reimbursement issues and other factors are creating obstacles in the Non-Alcoholic Steatohepatitis Market growth

Scope of Non-Alcoholic Steatohepatitis Pipeline Drug Insight    

• Coverage: Global
• Key Non-Alcoholic Steatohepatitis Companies: Gmax Biopharm, Novartis Pharmaceuticals, Lin Biosciences, Viking Therapeutics, Seal Rock Therapeutics, AstraZeneca, Boehringer Ingelheim, Oramed Pharmaceuticals, ENYO Pharma, Terns Pharmaceuticals, NovoNordisk, Madrigal Pharmaceuticals, Inventiva Pharma, Gilead Sciences, Enanta Pharmaceuticals, Inc., Genfit, JD Bioscience Inc., Oramed, Ltd., Merck Sharp & Dohme LLC, Regeneron Pharmaceuticals, Enyo Pharma, Terns, Inc., Galectin Therapeutics Inc., Oasis Pharmaceuticals, LLC, and others
• Key Non-Alcoholic Steatohepatitis Therapies: GMA-107, Tropifexor (LJN452), LBS-009, VK-1430, SRT-015, AZD 2693, BI 456906, ORMD-0801, EYP001, TERN-501, Semaglutide, Resmetirom, Lanifibranor, Semaglutide (SEMA), EDP-305, GFT505, GM-60106, ORMD-0801, MK-3655, ALN-HSD, EYP001a, TERN-201, GR-MD-02, OA-235i, and others
• Non-Alcoholic Steatohepatitis Therapeutic Assessment: Non-Alcoholic Steatohepatitis current marketed and Non-Alcoholic Steatohepatitis emerging therapies
• Non-Alcoholic Steatohepatitis Market Dynamics: Non-Alcoholic Steatohepatitis market drivers and Non-Alcoholic Steatohepatitis market barriers 

Request for Sample PDF Report for Non-Alcoholic Steatohepatitis Pipeline Assessment and clinical trials

Table of Contents

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services